AUTISM: Publication of the world's first integrative model of ASD development outlining the mechanisms and dynamics of ASD pathogenesis

Téléchargez la version?anglaise?ou?fran?aise?de l'annonce de la publication et l'invitation à?table ronde Biofit les?29 et 30?Novembre 2022

Download the Post in ENGLISH or FRENCH

Do not hesitate to share, you will help parents and children

We are proud to announce the publication of the world's first integrative neurodevelopmental model describing the mechanisms and dynamics of ASD pathogenesis from pregnancy to child early life: "Autism Spectrum Disorders pathogenesis: Toward a comprehensive model based on neuroanatomic and neurodevelopment considerations".?(download pdf open access), the latest output of the "GEMMA (Autism & microbiota) H2020 program" launched in 2019.

This is the 2nd in a series of 4 publications with Harvard Medical School. The first presented a novel mechanistic hypothesis on the interaction between the microbiome and the host in ASD affected individuals (This article belongs to the Special Issue Microbiome, Probiotics and Autism): "Autonomic Nervous System Neuroanatomical Alterations Could Provoke and Maintain Gastrointestinal Dysbiosis in Autism Spectrum Disorder (ASD):?A Novel Microbiome–Host Interaction Mechanistic Hypothesis".??(download pdf open access). The third will further explain the relative weight of epigenetics and RNA editing mechanisms in the development of ASD, while the fourth will conclude the overall neurodevelopmental model. We are open to talk about the therapy CADI-T2011 for Autism/ASD core symptoms attenuation ready for validation.

Furthermore, BIO-MODELING SYSTEMS, at the forefront of the necessary digital transformation of R&D processes since 2004, is invited to the Biofit Event in Strasbourg to participate to the round table "How is the digital era shaping new forms of early-stage collaborations in biopharma" . This will be a great opportunity to explain how BMSYSTEMS created CADI Discovery in 2004, successfully combining, Human and Artificial intelligence, to generate unique heurisitic non-mathematical models with the help of with its Integrative biologists, ever since.

With a world's first in the field of neurodegenerative diseases, 1 therapeutic start-up, and the launch of Telesphore-Pharma,?BMSystems' 2nd therapeutic start-up project in 2022,?this announcement confirms the excellence of BMSystems?in delivering value to patients and shareholders.

Created in 2004, profitable since 2006, thanks to our recurrent clients, BMSystems addresses two complementary?business targets:?

• For R&D, Translational Medicine & Digital Health Executives, we offer robust alternative decision-making to de-risk, save time and costs of R&D and Digital Health programs,
• For Business Developers, Patients Groups & Investors, we discover novel low-risk, highly effective and cost-effective diagnostic, therapy, nutrition, cosmetic, bioprocess solutions for spin-offs or out-licensing.

We warmly invite you?to?attend the Biofit event (November 29-30, 2022 in Strasbourg and December 7-8, 2022 (through the web) to meet us and visit our new website?to discover our achievements in diagnostics, therapeutics, cosmetics,?digital-Health and bio-processes.

Do not hesitate to contact us for more information or any business request. Download our latest presentation.

Best regards,

Manuel GEA

CEO Bio-Modeling Systems

About Bio-Modeling Systems

Bio-Modeling Systems is?the world’s first Mechanisms-Based medicine company?that changed the discovery paradigm to create novel medical meanings?from unreliable heterogeneous sources of data to generate validated?& directly exploitable first in class?heuristic non-mathematical mechanistic CADI? models. Bio-Modeling Systems is a 100% biology driven company focused on discovery, and critical high impact decisions making and address the following Markets: Pharma, Cosmetics, Nutrition, Health Technologies, Connected health with its dual business model: Contractual or Collaborative R&D programs. For all details and presentations, visit our new website.?